TY - JOUR
T1 - Localization of urokinase-type plasminogen activator receptor on U937 cells
T2 - phorbol ester PMA induces heterogeneity
AU - Hansen, S H
AU - Behrendt, N
AU - Danø, K
AU - Kristensen, P
PY - 1990/4
Y1 - 1990/4
N2 - The binding of human urokinase-type plasminogen activator (u-PA) to the surface of the human monocytic cell line U937 was studied by immunological detection of bound u-PA or binding of biotinylated diisopropyl fluorophosphate-inactivated human u-PA visualized by light or electron microscopy. Untreated U937 cells showed a characteristic binding pattern, with the majority of the u-PA bound to the microvillar-containing protruding pole of the cells. After treatment with the phorbol ester PMA, the resulting adherent cell population was very heterogeneous with respect to both cellular morphology and u-PA binding. The bound u-PA was distributed on both the dorsal and the substrate side of the cells, and the patches of bound u-PA could not be correlated to any typical membrane conformations or cell-cell or cell-substratum contacts. When a monoclonal antibody directed against the amino-terminal fragment (ATF) of u-PA was used, the results were identical regardless of whether intact u-PA or ATF was used for binding to the cells. In contrast, when a monoclonal antibody recognizing the non-receptor-binding protease domain of u-PA was used, bound ATF showed no staining, while bound intact u-PA was stained as efficiently as above. The alteration of u-PA receptor distribution following treatment with PMA could be related to the changes in glycosylation and ligand affinity of the purified u-PA receptor previously described following PMA treatment of U937 cells.
AB - The binding of human urokinase-type plasminogen activator (u-PA) to the surface of the human monocytic cell line U937 was studied by immunological detection of bound u-PA or binding of biotinylated diisopropyl fluorophosphate-inactivated human u-PA visualized by light or electron microscopy. Untreated U937 cells showed a characteristic binding pattern, with the majority of the u-PA bound to the microvillar-containing protruding pole of the cells. After treatment with the phorbol ester PMA, the resulting adherent cell population was very heterogeneous with respect to both cellular morphology and u-PA binding. The bound u-PA was distributed on both the dorsal and the substrate side of the cells, and the patches of bound u-PA could not be correlated to any typical membrane conformations or cell-cell or cell-substratum contacts. When a monoclonal antibody directed against the amino-terminal fragment (ATF) of u-PA was used, the results were identical regardless of whether intact u-PA or ATF was used for binding to the cells. In contrast, when a monoclonal antibody recognizing the non-receptor-binding protease domain of u-PA was used, bound ATF showed no staining, while bound intact u-PA was stained as efficiently as above. The alteration of u-PA receptor distribution following treatment with PMA could be related to the changes in glycosylation and ligand affinity of the purified u-PA receptor previously described following PMA treatment of U937 cells.
KW - Cell Line
KW - Cell Membrane
KW - Dexamethasone
KW - Enzyme Precursors
KW - Humans
KW - Immunoenzyme Techniques
KW - Immunohistochemistry
KW - Lymphoma, Large B-Cell, Diffuse
KW - Microscopy, Electron
KW - Receptors, Cell Surface
KW - Receptors, Urokinase Plasminogen Activator
KW - Tetradecanoylphorbol Acetate
KW - Tumor Cells, Cultured
KW - Urokinase-Type Plasminogen Activator
M3 - Journal article
C2 - 2156717
SN - 0014-4827
VL - 187
SP - 255
EP - 262
JO - Experimental Cell Research
JF - Experimental Cell Research
IS - 2
ER -